Why batch processing fails pharmaceutical solid dosage production
Batch processing imposes structural constraints on pharmaceutical solid dosage manufacturing that continuous processing is architecturally designed to eliminate. Fixed process settings, large buffer volumes, backmixing of material streams, and offline quality control are not incidental weaknesses — they are inherent to the batch paradigm itself, as articulated directly in the patent literature from GEA Pharma Systems’ tablet production module (2012).
The GEA Pharma Systems patent record explicitly states that batch (intermittent) manufacturing processes have many advantages and have provided satisfactory results in many respects, but the level of quality monitoring and control achievable through batch processes is generally insufficient because settings are fixed, and relatively large buffer volumes are required, generating unwanted backmixing of material streams and limiting traceability of manufactured product. The same record identifies the scale-up failure mode with precision: achieving higher production output through batch processes requires larger equipment, larger buffer volumes, and different process settings — whereas achieving higher output through continuous processes requires only longer run times while maintaining identical settings.
In pharmaceutical solid dosage manufacturing, batch processing requires larger equipment, larger buffer volumes, and different process settings to increase production output, whereas continuous manufacturing requires only longer run times at identical settings — directly eliminating the scale-up problem, as documented in GEA Pharma Systems’ tablet production module patent (2012).
SmithKline Beecham’s foundational US patent on pharmaceutical production apparatus specifies the quality control failures of batch processing with equal clarity: off-line batch-sampling techniques add time to the overall manufacturing process, are labour-intensive, and do not enable real-time detection of dosing errors. This IP family explicitly targets the elimination of incorrect-dose product through continuous movement of carrier substrates and inline dispensing control — representing one of the earliest systematic continuous solid dosage manufacturing architectures in the patent record.
Warner Lambert Company identified a further structural deficiency specific to granulation: conventional convective drying in batch systems requires large air flows or long residence times to achieve required moisture reduction, which can degrade or damage the manufactured pharmaceutical product. The continuous granulation system disclosed in Warner Lambert’s 2004 patent was designed specifically to resolve these degradation risks by replacing batch convective drying with radio frequency or microwave-based continuous drying.
Backmixing occurs when material streams in a batch vessel intermingle in an uncontrolled way, making it impossible to trace which input material produced which output product. In pharmaceutical manufacturing, backmixing limits the traceability of manufactured product and prevents real-time quality assurance — a core regulatory requirement under frameworks such as those published by FDA and the EMA.
Core technical mechanisms of continuous solid dosage manufacturing
The dominant technical mechanisms in the continuous pharmaceutical solid dosage patent landscape fall into four categories: twin-screw granulation with microwave or radio frequency drying, continuous API impregnation onto porous carriers, continuous liquid dose dispensing onto carrier substrates, and integrated tablet compression modules with inline upstream analytics. Each mechanism directly addresses a specific failure mode of batch processing.
Twin-screw granulation and continuous drying
Warner Lambert Company’s foundational continuous granulation architecture — filed in Mexico in 2003 — incorporates multiple feeders for powders and liquids, a twin-screw processor for granulation, a radio frequency or microwave-based drying apparatus, and at least one mill to process the dried granulation to desired particle sizes. Online monitoring of key process parameters operates across all components, controlled by a feedback controller at each stage. The granulation output can be directly compressed into tablets or filled into capsules with uniform API distribution, and the system maintains consistent product properties even at commercial-scale production volumes. This single-pass architecture directly solves the scale-up problem inherent to batch systems.
Warner Lambert Company’s continuous pharmaceutical granulation system uses a twin-screw processor combined with radio frequency or microwave-based drying to produce granules in a single pass, maintaining consistent product properties at commercial-scale production volumes and eliminating the degradation risks of batch convective drying (Mexico patent, 2003).
BASF Aktiengesellschaft patented a complementary continuous solid particulate preparation process using a screw extruder divided into multiple zones: a heatable zone where matrix auxiliaries are melted and bioactive components are homogeneously dispersed, followed by a cooling zone with conveying, mixing, and kneading geometry (Brazil, 2009). This hot-melt extrusion approach to continuous solid dispersion preparation enables the production of bioactive solid particles in a thermoplastic matrix without the batch-to-batch variability of conventional wet granulation followed by batch drying.
Continuous API impregnation onto porous carriers
Rutgers, The State University of New Jersey disclosed a continuous process for impregnating active pharmaceutical ingredients onto porous carriers that bypasses granulation entirely. The process continuously directs a porous carrier from a first feeder into a continuous blender equipped with one or more nozzles, through which an API-in-solvent solution is continuously introduced to form API-impregnated porous carrier, which is then continuously dried using a fluidized bed dryer to form a powder. The resulting powder feeds directly into downstream tablet or capsule manufacturing unit operations, forming a fully continuous end-to-end chain (Rutgers, 2021).
Continuous liquid dose dispensing onto carrier substrates
SmithKline Beecham Corporation (later GlaxoSmithKline LLC) developed a continuous manufacturing platform that dispenses a liquid dose of active material onto a solid carrier substrate during continuous movement of the substrate on a conveyor, followed by drying and real-time monitoring of the amount of active material deposited. The US-jurisdiction patent from this family specifies a content uniformity performance target of less than 2% relative standard deviation (RSD) for doses below 10 mg — a specification explicitly enabled by the continuous inline dispensing architecture and stated to be unachievable reliably through batch processes (SmithKline Beecham, US, 2006).
“A content uniformity performance target of less than 2% relative standard deviation (RSD) for doses below 10 mg is explicitly enabled by the continuous inline dispensing architecture and stated to be unachievable reliably through batch processes.”
Integrated tablet compression modules with inline analytics
GEA Pharma Systems Limited’s contained tablet production module places API and excipient inlets in fluid communication with at least one mixing unit, with the tablet press outlet in fluid communication with a releasable output port for finished tablets. During operation, one or more analytical sensors upstream of the tablet press measure parameters of the material stream contents, and the speed of the tablet press is controlled in response to those measured upstream parameters (GEA Pharma Systems, Brazil, 2019). This closed-loop tablet press speed control based on real-time upstream API concentration measurement replaces the batch paradigm in which process parameters are set before the run and quality is confirmed only after batch completion.
GEA Pharma Systems’ tablet production module uses inline upstream analytical sensors to control tablet press speed in real time based on measured API concentration in the material stream. This architecture replaces end-of-batch release testing — the central quality control bottleneck in batch pharmaceutical manufacturing — and is consistent with ICH Q8/Q10 process analytical technology (PAT) principles.
Explore the full patent landscape for continuous pharmaceutical manufacturing in PatSnap Eureka.
Explore Patent Data in PatSnap Eureka →Modular architectures: scalability and multi-product flexibility
A recurring architectural principle across the continuous solid dosage patent data is modularity — designing systems as connected, independently controllable unit operations that can be reconfigured or scaled without fundamental process redesign. This principle addresses both the scale-up problem and the multi-product flexibility challenge that batch systems historically required separate production lines to solve.
Robert Bosch GmbH and Hüttlin GmbH have each developed production modules for solid medicaments that pass individual batches through a controlled sequence of supply, mixing, and final processing devices. The Bosch system employs diverters between the supplying device, mixing device, and final working device to transfer material without remixing, maintaining the identity and traceability of discrete material portions within an otherwise continuous process flow (Robert Bosch GmbH, US, 2020). The parallel Hüttlin GmbH system uses collection airlocks between the supply, mixing, and final processing devices to prevent remixing between discrete batches within the module (Hüttlin GmbH, ES, 2021).
Massachusetts Institute of Technology’s continuous tablet manufacturing system can produce tablets of different API dosages without shutting down or switching off unit operations during product changeover, blending API and excipient in volumes of less than 10 L — directly replacing large-volume batch blending (MIT Brazil patent, 2020).
Massachusetts Institute of Technology has addressed the multi-product flexibility challenge directly. Their continuous tablet system can manufacture tablets of different dosages without the need to fluidically switch on or off unit operations when changing from a first dosage to a second dosage, and can also manufacture composition tablets with different APIs in the same continuous system. The companion Mexican patent specifies blending first and second amounts of API and excipient in volumes of less than 10 L to form first and second tablets with different API dosages — a direct replacement of large-volume batch blending (MIT, Mexico, 2019).
GlaxoSmithKline LLC separately patented a continuous pellet coating apparatus that uses vibrational impulses to maintain dosage forms in a fluid state for exposure to atomized coating material (GlaxoSmithKline LLC, ES, 2015), extending the continuous processing paradigm through the coating unit operation — a stage that has historically been a major bottleneck in batch pan-coating systems.
Fette Compacting GmbH represents the most recent filing in the dataset (EP, pending, 2025), covering a method and device for configuring a continuous processing system that comprises powder feeders and a mixing device, enabling dynamic adjustment of powder material feed and mixing parameters — indicating continued active innovation in continuous powder processing system configuration.
Triastek Inc. has developed high-throughput pharmaceutical additive manufacturing (3D printing) systems that use a flow distribution plate with multiple channels to split a single material stream into multiple parallel streams delivered to multiple needle-valve nozzles, enabling simultaneous printing of multiple dosage units with nozzle-specific parameter control (Triastek Inc., WO, 2021). This represents the emerging convergence of continuous manufacturing with pharmaceutical 3D printing as reported in research published by Nature.
Map the full continuous manufacturing IP landscape with PatSnap Eureka’s patent intelligence tools.
Analyse Patents with PatSnap Eureka →The patent landscape: dominant IP holders and innovation trends
The continuous pharmaceutical solid dosage manufacturing patent landscape is concentrated among a small number of assignees with distinct technical specialisations, filing strategies, and geographic footprints. Based on frequency of appearance and technical scope across the 50+ patent records analysed, six organisations hold the most strategically significant IP positions.
SmithKline Beecham Corporation / GlaxoSmithKline LLC is the most prolific assignee in the dataset, holding a globally filed patent family covering continuous liquid-dose dispensing onto carrier substrates with real-time release. This family spans the US, EP, AU, IN, MX, NO, NZ, TW, KR, JP, HK, CA, IL, and BR jurisdictions — representing the broadest geographic coverage of any single continuous solid dosage manufacturing concept in the data.
GEA Pharma Systems Limited holds key patents in the tablet compression module space covering upstream inline analytics and tablet press speed control architecture, filed across BR, ES, PT, and CN jurisdictions. Warner Lambert Company established foundational prior art in continuous pharmaceutical granulation using twin-screw processing and microwave drying, filed in MX and JP jurisdictions. Massachusetts Institute of Technology represents the academic-institutional innovation axis, with patents covering flexible, multi-dosage continuous tablet systems filed in BR and MX.
Triastek Inc. is the most active recent filer in the dataset, with multiple active patents across WO, CA, JP, and CN jurisdictions covering high-throughput pharmaceutical additive manufacturing systems — reflecting the emerging convergence of continuous manufacturing with 3D printing. BASF Aktiengesellschaft and Rutgers, The State University of New Jersey each hold significant process-level IP in continuous solid dispersion (hot-melt extrusion) and continuous API-porous carrier impregnation, respectively.
SmithKline Beecham Corporation / GlaxoSmithKline LLC holds the most geographically extensive patent family in continuous pharmaceutical solid dosage manufacturing, covering the US, EP, AU, IN, MX, NO, NZ, TW, KR, JP, HK, CA, IL, and BR jurisdictions — 14 or more territories — for their continuous liquid-dose dispensing onto carrier substrates platform.
The filing timeline across the dataset reveals a clear innovation arc: foundational continuous granulation and dispensing architectures were established between 2003 and 2007 by Warner Lambert and SmithKline Beecham/GSK; integrated tablet compression modules with inline analytics emerged between 2012 and 2019 from GEA Pharma Systems; and the most recent innovations (2019–2025) are concentrated in multi-dosage flexible systems (MIT), pharmaceutical additive manufacturing (Triastek), and configurable continuous processing system design (Fette Compacting). This progression reflects the maturation of continuous manufacturing from a process-level innovation to a systems-level platform, consistent with trends tracked by the WIPO in pharmaceutical technology patent filings.
The involvement of Rutgers University and MIT alongside commercial entities such as GEA, GSK, BASF, and Triastek signals that continuous pharmaceutical manufacturing has attracted both industrial and academic IP investment — a pattern typical of technologies approaching broad commercial adoption, as documented in WIPO’s Global Innovation Index methodology for technology readiness assessment.